Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Releases

778 Press Releases
DateTitleCompany
25 May 17 FDA Advisory Committee Recommends Approval of Pfizer’s Proposed Biosimilar to Epogen®/Procrit® Across All Indications Pfizer Inc.,
Published by
Business Wire
17 May 17 Pfizer Invites Public to View and Listen to Webcast of June 9 Conference Call with Analysts to Review Oncology Business and ASCO Data Presentations Pfizer Inc.,
Published by
Business Wire
04 May 17 Robert C. Rickert Joins Pfizer as Chief Scientific Officer of Rinat to Lead Early Discovery Efforts in Immuno-Oncology Pfizer Inc.,
Published by
Business Wire
03 May 17 Pfizer Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application for XELJANZ® (tofacitinib citrate) for the Treatment of Adult Patients with Active Psoriatic Arthritis Pfizer Inc.,
Published by
Business Wire
27 Apr 17 Pfizer’s Next-Generation ALK/ROS1 Inhibitor, Lorlatinib, Granted Breakthrough Therapy Designation from FDA for ALK-Positive Metastatic Non-Small Cell Lung Cancer Pfizer Inc.,
Published by
Business Wire
24 Apr 17 Pivotal Phase III Study Underscores Efficacy Of Zavicefta™ (ceftazidime-avibactam) For Treatment Of Hospital-Acquired Pneumonia, A Leading Cause Of Mortality In Hospitals Pfizer,
Published by
Business Wire
21 Apr 17 Pfizer Receives Positive CHMP Opinion for BESPONSA® (Inotuzumab Ozogamicin) for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia Pfizer Inc.,
Published by
Business Wire
21 Apr 17 Pfizer Unveils ATLAS®, An Interactive, User-Friendly Website That Provides Global Antibiotic Resistance Surveillance Data Across 60 Countries Pfizer Inc.,
Published by
Business Wire
20 Apr 17 Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders Pfizer Inc.,
Published by
Business Wire
27 Mar 17 XELJANZ® (tofacitinib citrate) Receives Marketing Authorisation in the European Union for the Treatment of Moderate to Severe Active Rheumatoid Arthritis (RA) Pfizer Inc.,
Published by
Business Wire
27 Mar 17 FDA Grants Approval for BAVENCIO® (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma Merck-Pfizer Alliance,
Published by
PharmiWeb.com
22 Mar 17 Pfizer Invites Public to View and Listen to Webcast of May 2 Conference Call with Analysts Pfizer Inc.,
Published by
Business Wire
14 Mar 17 Pfizer Launches Zavicefta™ (ceftazidime-avibactam) in the U.K. and Germany, a New Antibiotic to Treat Complicated Infections Caused by Gram-Negative Bacteria Pfizer Inc.,
Published by
Business Wire
01 Mar 17 Pfizer Prices €4,000,000,000 Debt Offering Pfizer Inc.,
Published by
Business Wire
28 Feb 17 FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review EMD Serono and Pfizer,
Published by
PR Newswire
28 Feb 17 FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Urothelial Carcinoma for Priority Review Merck and Pfizer,
Published by
PR Newswire
24 Feb 17 Pfizer Prices $1,065,000,000 Debt Offering Pfizer Inc.,
Published by
Business Wire
23 Feb 17 Ronald E. Blaylock Elected to Pfizer’s Board of Directors Pfizer Inc.,
Published by
Business Wire
19 Dec 16 Pfizer Receives Approval in the European Union for Nimenrix™ (Meningococcal Group A, C, W-135, and Y Conjugate Vaccine) in Infants Six Weeks of Age and Older Pfizer Inc.,
Published by
Business Wire
05 Jan 17 Pfizer Announces Positive Top-Line Results from the Comparative REFLECTIONS B538-02 Study for PF-06410293, a Potential Biosimilar to Humira®1 (adalimumab) Pfizer Inc.,
Published by
Business Wire
15 Dec 16 CORRECTING and REPLACING Pfizer Receives FDA Approval for EUCRISA™ (crisaborole), a Novel Non-Steroidal Topical Ointment for Mild to Moderate Atopic Dermatitis (Eczema) Pfizer Inc.,
Published by
Business Wire
23 Dec 16 Pfizer Completes Acquisition of Small Molecule Anti-Infective Business From AstraZeneca Pfizer Inc.,
Published by
Business Wire
21 Feb 17 Pfizer Announces Acceptance of Regulatory Submission for Inotuzumab Ozogamicin by the U.S. Food and Drug Administration Pfizer Inc.,
Published by
Business Wire
12 Dec 16 Pfizer Declares First-Quarter 2017 Dividend Pfizer Inc.,
Published by
Business Wire
27 Jan 17 Pfizer Receives Positive CHMP Opinion in Europe for XELJANZ® (tofacitinib citrate) for the Treatment of Moderate to Severe Active Rheumatoid Arthritis Pfizer Inc.,
Published by
Business Wire
26 Jan 17 Pfizer Announces Positive Top-Line Results from Phase 2 Study of Investigational Clostridium difficile Vaccine for the Prevention of C. difficile Infection Pfizer Inc.,
Published by
Business Wire
03 Dec 16 New Phase 2 Results Show Investigational Compound Glasdegib Improved Overall Survival in Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Pfizer Inc.,
Published by
Business Wire
17 Feb 17 New Data in Crohn’s Disease Patients Shows Similar Efficacy and Safety Profiles for INFLECTRA® and REMICADE®a Pfizer Inc.,
Published by
Business Wire
16 Feb 17 Pfizer Announces Top-Line Results from the Oral Strategy Trial of XELJANZ® (tofacitinib citrate) Compared to Humira® (adalimumab) Pfizer Inc.,
Published by
Business Wire
21 Dec 16 FDA Accepts Supplemental New Drug Application for Pfizer’s IBRANCE® (palbociclib) in HR+, HER2- Metastatic Breast Cancer Pfizer Inc.,
Published by
Business Wire
Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.